296
Participants
Start Date
September 12, 2016
Primary Completion Date
February 26, 2021
Study Completion Date
February 16, 2022
mirabegron
50 mg daily during 12 months
Echocardiography
Echocardiography
Cardiac MRI
Cardiac MRI
Maximal exercise capacity
Maximal exercise capacity
Blood sampling
Blood sampling for study assessments and future exploratory studies.
Endothelial function measurement
EndoPAT assessment
18FDG-PET
PET scanning for beige/brown fat activation
Cliniques universitaires Saint-Luc, Brussels
Center for Cardiovascular Research Berlin (CCR/Charité), Berlin
University Medical Center Göttingen (UMG-GOE), Göttingen
Nantes university hospital (CHU Nantes), Nantes
University of Leipzig, Leipzig
Athens University Medical School (NKUA), Athens
"Hospital Papa Giovanni XXIII (HPG23)", Bergamo
Department of Heart Diseases at Wroclaw Medical University (UMW), Wroclaw
Association for Research and Development of the Faculty of Medicine (AIDFM), Lisbon
University of Oxford - Division of Cardiovascular Medicine (UOXF), Oxford
Zentrum für Klinische Studien Leipzig
OTHER
European Clinical Research Infrastructure Network
OTHER
European Society of Cardiology
NETWORK
European Commission
OTHER
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
OTHER
Northern Lisbon Hospital Center
OTHER
University of Athens
OTHER
Center for Cardiovascular Research Berlin
OTHER
Wroclaw Medical University
OTHER
Papa Giovanni XXIII Hospital
OTHER
Nantes University Hospital
OTHER
University Medical Center Goettingen
OTHER
University of Oxford
OTHER
Jean-Luc Balligand
OTHER